Sickle Cell Matters

Posted: September 10, 2021

It’s Not Just Support. It’s Solutions.

September is National Sickle Cell Awareness Month, a time to acknowledge and educate how this often-invisible and rare disease impacts over 100,000 people in the U.S., most of whom are of African descent. Treatment can include antibiotics, pain management, intravenous fluids, blood transfusion and surgery.

Sickle Cell Disease Association of America (SCDAA) theme for 2021 is Sickle Cell Matters. DiaPharma celebrates the Scientists and Medical Professionals helping to advance knowledge, awareness, and treatment options for Sickle Cell Disease.

Sickle Cell

Tools for Sickle Cell Disease Research

From HbS flow cytometry antibodies, coagulation kits and biomarker assays to exciting new instrumentation for clotting analysis, DiaPharma has what matters covered for impactful Sickle Cell Research.

Anti-Hemoglobin S antibodies from DiaPharma for flow cytometry applications

Item	Clone	Description	Product Code
Anti-HbS FITC	57-8	Anti-Hemoglobin S antibody conjugated with fluorochrome FITC	IQP-574F
Anti-HbF1 Dy-410	WBAC HbF1	Anti-Hemoglobin F antibody conjugated with fluorochrome Dy-410	IQP-567D
Anti-HbF1 FITC	WBAC HbF1	Anti-Hemoglobin F antibody conjugated with fluorochrome FITC	IQP-567F
Anti-HbF1 R-PE	WBAC HbF1	Anti-Hemoglobin F antibody conjugated with fluorochrome R-PE	IQP-567R
Anti-panHb APC	PHB1	Anti-pan Hemoglobin antibody conjugated with fluorochrome APC	IAP-585A

Regulatory Status: Analyte Specific Reagent (ASR). Analytical and performance characteristics are not established.

Coagulation Markers in Research

It is suggested that aberrant coagulation and platelet overactivation contribute to the pathogenesis of SCD. Further research and clinical trials are needed to explore the mechanisms driving abnormal coagulation in SCD and to identify effective therapies to treat it. DiaPharma offers a range of assays to further SCD research:

Coagulation Factors	Components	Function	Biomarkers and Methods of Evaluation	Activity in Sickle Cell Disease
Extrinsic Pathway	Tissue factor (TF) FVII	Primary pathway to initiate coagulation following vascular endothelial injury	Prothrombin time (PT)	Increased TF expression
Intrinsic Pathway	Prekallikrein HMWK, FXII, FXI	Activated by exposed collagen in the subendothelium and functions to initiate clot formation	Activated partial thromboplastin time (aPTT)	Decreased Prekallikrein, FXII, and HMWK plasma levels Increased levels of procoagulant microparticles
Common Pathway	FV, FVIII, FIX, FX thrombin FXIII fibrin	Catalysts in the final steps of coagulation to cleave fibrinogen and form blood clots	Thrombin Generation Assays (TGA), TAT, PAP, F1.2, D-dimers, fibrinogen	Increased thrombin levels
Fibrinolysis	Plasmin	Enzymatic degradation of fibrin in blood clots	uPA, tPA, PAI-1, D-dimers	Increased fibrinolytic activity
Platelet Activation	Collagen Fibrinogen, vWF ADAMTS-13	Platelets activate and aggregate to form a platelet plug	vWF, ADAMTS-13, Platelet Function Tests	Increased platelet numbers, platelet activation, and platelet aggregation
Complement System	C3a C5a	Activated by the coagulation system and contributes to thrombus formation	C3a and C5a	Increased C3a and C5a expression
Anticoagulation Proteins	Protein C Protein S	Negative feedback to regulate coagulation and inflammation	Protein C Protein S	Decreased Protein C and Protein S levels

Automated Measurement of Primary and Secondary Hemostasis Markers

Instrument	Fully Automated Coagulation Analyzer	Clot Growth & Fibrinolysis Dynamics	Primary Hemostasis and Platelet Function Testing
Instrument	Ceveron® 100 Series	Thrombodynamics	T-TAS® 01	Atlas PST

Ceveron® series, Thrombodynamics®, and Atlas® PST are for research use only. Not for use in diagnostic procedures.

It’s Not Just Support. It’s Solutions.

Over 20 years of scientific expertise, with support just a call or click away.

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846

ML-00-00855Rev01